GlassScriptPhysician profile
Daniel John Mazur
NPI 1356636542
$2,483.18
in general payments reported to CMS, 2019-2025
25 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $196 · 2021: $347 · 2022: $125 · 2023: $217 · 2024: $312 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,032.07 | 2019-2025 | Ams 800 Artificial Urinary Sphincter |
| Coloplast Corp | $187.03 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.96 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $131.31 | 2020-2025 | Provenge |
| Sumitomo Pharma America, INC. | $120.53 | 2024-2025 | Orgovyx, Gemtesa |
| 180 Medical, INC. | $119.23 | 2019-2024 | |
| Abbvie INC. | $105.33 | 2019-2025 | |
| Antares Pharma, INC. | $76.52 | 2022-2025 | Xyosted |
| Progenics Pharmaceuticals, INC. | $74.06 | 2021-2025 | Pylarify |
| Myovant Sciences INC. | $67.94 | 2021 | |
| Janssen Biotech, INC. | $48.55 | 2021 | |
| Teleflex LLC | $46.18 | 2025 | Barrigel |
| Tolmar, INC. | $45.65 | 2025 | Jatenzo, Eligard |
| Myriad Genetic Laboratories, INC. | $41.85 | 2021 | |
| Valencia Technologies Corporation | $35.58 | 2024 | Ecoin Device Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $34.85 | 2024-2025 | |
| Astellas Pharma US INC | $25.30 | 2023 | Xtandi |
| Medtronic, INC. | $23.21 | 2025 | Altaviva |
| Pfizer INC. | $22.61 | 2023 | |
| Laborie Medical Technologies Corp. | $21.64 | 2023 | |
| Aytu Biopharma, INC. | $18.05 | 2019 | |
| Olympus America INC. | $16.52 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $16.50 | 2020 | |
| Allergan, INC. | $14.49 | 2022 | |
| Foundation Medicine, INC. | $13.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mazur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.